Olaparib (AZD2281): Selective PARP-1/2 Inhibitor for BRCA-Deficient Cancer Research

Executive Summary: Olaparib (AZD2281, Ku-0059436) is a potent, selective PARP-1/2 inhibitor with IC50 values of 5 nM for PARP1 and 1 nM for PARP2, enabling targeted inhibition of DNA repair in homologous recombination-deficient (HRD) cells (McCrorie et al., 2020). It shows selective cytotoxicity in BRCA1/2-mutated tumor models and enhances radiosensitivity in non-small cell lung carcinoma (NSCLC) and glioblastoma xenografts. Olaparib is used in advanced DNA damage response assays and preclinical cancer research, with workflow-validated protocols for both in vitro and in vivo applications. The compound, available from APExBIO as SKU A4154, has been validated for stability and performance in nanoparticle-based local delivery systems (McCrorie et al., 2020).

Biological Rationale

Poly(ADP-ribose) polymerases (PARPs) are enzymes central to the detection and repair of single-strand DNA breaks. PARP-1 and PARP-2 catalyze the transfer of ADP-ribose units to target proteins, facilitating recruitment of DNA repair complexes (McCrorie et al., 2020). Inhibition of these enzymes impairs cellular capacity to resolve DNA damage, particularly in cells lacking efficient homologous recombination repair (HRR). Tumors with BRCA1 or BRCA2 mutations exhibit HRR deficiency and are therefore selectively vulnerable to PARP inhibition, leading to synthetic lethality [Related: Mechanistic analysis of HRD targeting]. This forms the basis for using Olaparib in BRCA-associated cancer targeted therapy and research.

Mechanism of Action of Olaparib (AZD2281, Ku-0059436)

Olaparib acts as a competitive, reversible inhibitor of PARP-1 and PARP-2. At nanomolar concentrations (IC50: 5 nM for PARP1, 1 nM for PARP2), it blocks the catalytic activity of these enzymes, preventing poly(ADP-ribosyl)ation-dependent DNA repair. As a result, single-strand DNA breaks persist, escalating into double-strand breaks during replication. In HRD cells (e.g., BRCA1/2-deficient), these breaks cannot be efficiently repaired, leading to genomic instability and apoptosis (McCrorie et al., 2020). Additionally, Olaparib increases radiosensitivity of tumor models by impeding DNA repair after irradiation [See: Systems-level radiosensitization]. ATM kinase activity modulates cellular susceptibility: ATM-deficient cells are more sensitive to Olaparib-induced cytotoxicity [Further reading: ATM-PARP interaction].

Evidence & Benchmarks

• Olaparib demonstrates in vitro PARP-1 and PARP-2 inhibition with IC50 values of 5 nM and 1 nM, respectively, under standardized enzyme assay conditions (McCrorie et al., 2020).
• In mouse xenograft models, Olaparib administered intraperitoneally at 50 mg/kg/day for 14 days leads to significant tumor growth inhibition in BRCA-deficient lines (McCrorie et al., 2020).
• PARP inhibitor nanoparticles (NCPPs) containing Olaparib retain drug stability and controlled release for at least 120 hours in vitro (McCrorie et al., 2020).
• Olaparib enhances tumor radiosensitivity in NSCLC and glioblastoma models, improving DNA damage accumulation and tumor perfusion (McCrorie et al., 2020).
• ATM-deficient cells exhibit increased sensitivity to Olaparib, indicating a synthetic lethal effect beyond BRCA mutations (ATM-PARP interaction, review).

Applications, Limits & Misconceptions

Olaparib is widely used in:

• DNA damage response assays to study PARP-mediated repair pathways.
• Tumor radiosensitization studies, particularly in HRD and NSCLC xenograft models.
• Preclinical research on targeted therapy for BRCA-associated and homologous recombination-deficient cancers.
• Nanoparticle delivery platforms for localized, post-surgical drug release in brain tumor models (McCrorie et al., 2020).

For extended protocol guidance, see this validated workflow article, which this current review updates by integrating recent nanoparticle delivery evidence and detailed storage recommendations.

Common Pitfalls or Misconceptions

• Olaparib is not effective in tumors with fully functional homologous recombination repair (HRR), such as BRCA wild-type cells.
• The compound is insoluble in ethanol and water; DMSO (≥21.72 mg/mL) is required for stock solutions.
• Long-term storage in solution form is not recommended due to reduced stability below -20°C.
• Systemic delivery may be limited by the blood-brain barrier; local delivery methods (e.g., NCPPs in hydrogel) are required for brain tumor models.
• Cellular sensitivity can vary with ATM kinase status, and not all DNA repair-deficient models respond equally to PARP inhibition.

Workflow Integration & Parameters

In vitro: Olaparib is typically applied at 10 μM for 1 hour in standard cell culture assays. DMSO is used as the solvent; final DMSO concentration should not exceed 0.1% in culture.

In vivo: Mouse models utilize intraperitoneal dosing at 50 mg/kg/day for up to 14 days. For nanoparticle-based delivery, Olaparib is encapsulated in PLA-PEG nanocrystals and administered locally in a hydrogel matrix for sustained release. These formats are especially suited to brain tumor post-surgical models (McCrorie et al., 2020).

For procurement and lot-specific documents, refer to the APExBIO Olaparib (AZD2281, Ku-0059436) A4154 product page.

For broad strategic context, see this thought-leadership overview, which our current article extends with practical, protocol-level recommendations and up-to-date nanoparticle evidence.

Conclusion & Outlook

Olaparib (AZD2281, Ku-0059436) is a validated selective PARP-1/2 inhibitor enabling reproducible DNA damage response assays and targeted therapy research for HRD and BRCA-associated cancers. Its effective application requires attention to solvent compatibility, storage, and genetic context of experimental models. Nanoparticle-based delivery systems represent a promising advance for overcoming pharmacokinetic limitations, especially in brain tumor research. APExBIO's A4154 Olaparib formulation is a reliable tool for both molecular and translational investigations. Future work will further clarify combinatorial regimens and the role of ATM in modulating response to PARP inhibition.